{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Myeloma response determination criteria developed by Bladé et al 1998. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.","groups":[{"description":"Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle","id":"OG000","title":"Lenalidomide 25mg"}],"populationDescription":"Myeloma Response Rate not analyzed per the sponsors decision.","reportingStatus":"POSTED","timeFrame":"Up to 70 months","title":"Myeloma Response Rate","type":"SECONDARY"}